ストックスクリーナーアプリを入手
0.47
4.44%
0.02
前日終値:
$0.45
開ける：
$0.4549
24時間の取引高:
5.81M
Relative Volume:
0.89
時価総額：
$109.59M
収益：
$52.29M
当期純損益:
$-134.84M
株価収益率:
-0.6267
EPS:
-0.75
ネットキャッシュフロー:
$-117.11M
1週間 パフォーマンス:
-32.88%
1か月 パフォーマンス:
-31.42%
6か月 パフォーマンス:
-77.07%
1年 パフォーマンス:
-22.79%
1日の値動き範囲:
$0.449
$0.4879
1週間の範囲:
$0.4111
$0.7624
52週間の値動き範囲:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
名前
Sangamo Therapeutics Inc
セクター
電話
(510) 970-6000
住所
501 CANAL BLVD., RICHMOND, CA
SGMO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.47 | 160.48M | 52.29M | -134.84M | -117.11M | -0.75 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | アップグレード | Truist | Hold → Buy |
| 2024-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-02-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-01-07 | 再開されました | Guggenheim | Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-12-16 | 再開されました | H.C. Wainwright | Buy |
| 2020-09-08 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | SunTrust | Buy |
| 2019-08-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2018-10-10 | 開始されました | Guggenheim | Buy |
| 2018-06-20 | 開始されました | BofA/Merrill | Buy |
| 2017-11-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 再開されました | Jefferies | Buy |
| 2016-11-01 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-10-19 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-10-23 | 再開されました | Jefferies | Buy |
| 2013-05-03 | 開始されました | BioLogic Equity Research | Sell |
| 2011-02-23 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-07-29 | 繰り返されました | Wedbush | Outperform |
| 2009-10-19 | 開始されました | Brean Murray | Sell |
| 2009-10-07 | 繰り返されました | Leerink Swann | Outperform |
| 2009-08-25 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Sangamo Therapeutics Inc (SGMO) 最新ニュース
Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | - GuruFocus
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus
Sangamo Biosciences Announces $23 Million Share Offering - TipRanks
Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus
Sangamo Therapeutics prices $23M securities offering - MSN
Market Setbacks: Major Stocks Face Financial Hurdles - Finimize
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below - GuruFocus
Sangamo Therapeutics (SGMO) Q1 Earnings Miss Expectations - GuruFocus
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - BioSpace
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - BioSpace
Sangamo Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Sangamo Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Sangamo Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Earnings call transcript: Sangamo Therapeutics faces stock drop after Q1 2025 call - Investing.com Nigeria
Sangamo Therapeutics Reports Recent Business Highlights and Firs - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below Expectations | SGMO Stock News - GuruFocus
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwri - GuruFocus
Sangamo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sangamo Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - BioSpace
Sangamo: Q1 Earnings Snapshot - San Antonio Express-News
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Zenopa
Sangamo Therapeutics (SGMO) Anticipates Q1 Earnings Release - GuruFocus
Sangamo hits milestone toward accelerated approval for ST-920 - Fabry Disease News
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - BioSpace
Sangamo Biosciences Receives Nasdaq Deficiency Notice - TipRanks
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Zenopa
Sangamo advances gene therapy for Fabry disease By Investing.com - Investing.com India
Sangamo Therapeutics Announces Important Derisking Milestones in - GuruFocus
Sangamo advances gene therapy for Fabry disease - Investing.com
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease | SGMO Stock News - GuruFocus
Sangamo Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
Sangamo Therapeutics to Present Neurology Pipeline Advances at t - GuruFocus
Sangamo Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Sangamo Therapeutics, Inc. (SGMO) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Sangamo Therapeutics Inc (SGMO) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):